FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

BALPHARMA

95.2
+0.4 (0.42%)
Updated 03:28 30/07 IST

BALPHARMA Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for BALPHARMA
Disclaimer
0% Bullish
0% Bearish

BALPHARMA Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See BALPHARMA Share Price Targets >>

BALPHARMA Ratings

Long term BALPHARMA rating by FrontPage users
0/5 (0 Ratings)0
Find answers to all your questions on live BALPHARMA message board: Is BALPHARMA buy or sell? Should I buy BALPHARMA shares? Why are BALPHARMA shares falling? Should I invest in BALPHARMA stock?

  1. Home
  2. BALPHARMA Forum

BALPHARMA Share Price Discussion

N
Reputation: 13,930 • May 25 4:06 AM
Bal Pharma stock hits upper circuit on affordable Favipiravir launch
The scrip hit upper circuit of 5 per cent to Rs 98.40 on Tuesday. The counter was settled at Rs 93.75 in the previous session. BSE Sensex was trading 148.79 points or 0.29 per cent up at 50,800.69.
The Economic Times
Like
Reply
N
Reputation: 13,930 • May 24 12:41 PM
Bal Pharma launches antiviral drug Favipiravir at Rs 85/tablet
Bal Pharma Managing Director Shailesh Siroya said BALflu has the efficacy to clear the virus faster by 28.7 per cent and is marketed at a very affordable price of Rs 85 per tablet so as to enable the needy patients to access this drug on time.
The Economic Times
Like
Reply

Type
Buy
Instrument
BALPHARMA
Entry Price
₹109.55
Price@Trade
₹109.95
Target Price
₹150
Stop Price
₹95
Valid Till
Jun 4, 2021 3:20 AM
Margin
₹10,955 approx for 100 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
May 5 8:49 AM

Update
Trade Entered
Entry Price
₹109.55

Type
Sell
Instrument
BALPHARMA
Entry Price
₹115.65
Price@Trade
₹115.65
Target Price
₹109
Stop Price
₹122
Valid Till
May 6, 2021 3:20 AM
Margin
₹11,565 approx for 100 Qty
Status
Target Achieved
Exit Price
₹109
Net P&L
+₹665 (+5.75%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Apr 30 3:05 AM

Update
Target Achieved
Exit Price
₹109
Like
Reply
Like
Reply
HAR DIL AZIZ in BALPHARMA
Positional buy above 62 sl 51 Tgt 70...78...85+...

64.30 high made gap up open 🚀🚀🚀🚀🚀 #BALPHARMA
Like
Reply

Positional
buy above 62 sl 51 Tgt 70...78...85++++ #BALPHARMA
Like
Reply
Like
Reply

Type
Buy
Instrument
BALPHARMA
Entry Price
₹66.8
Price@Trade
₹66.8
Target Price
₹130
Stop Price
₹47
Valid Till
Nov 26, 2021 3:20 AM
Margin
₹66,800 approx for 1000 Qty
Status
Exited
Exit Price
₹66.8
Net P&L
₹0 (0%)
Like
Reply (1)
swap_vert
Trade
See all replies
Ravi Kumar @ravikumar-SJ1Ebds9v
Nov 27, 2020 5:38 AM

Update
Exited
Exit Price
₹66.8
Net P&L
₹0 (0%)

Type
Buy
Instrument
BALPHARMA
Entry Price
₹42.95
Price@Trade
₹42.95
Target Price
₹100
Stop Price
₹20
Valid Till
Jul 10, 2020 3:20 AM
Margin
₹42,950 approx for 1000 Qty
Status
Exited
Exit Price
₹44.05
Net P&L
+₹1,100 (+2.56%)
Like
Reply (1)
swap_vert
Trade
See all replies
Mohan M as MDT @mohanmMDT
Jun 16, 2020 4:24 AM

Update
Exited
Exit Price
₹44.05
Net P&L
+₹1,100 (+2.56%)

Watch
Btst + positional
Buy bal pharma cash
48.2-42.2
Sl 40.5
Tgt 55.5/60++
Based on Short-term breakout levels
Like
Reply (2)
See all replies
share bazaar update @sharebazaar
Jan 14, 2020 8:26 AM

Bal pharma made new day high
48.8💸
share bazaar update @sharebazaar
Jan 14, 2020 8:38 AM

49.1💸💸💸new day high
N
Reputation: 13,930 • Aug 28, 2019 1:38 AM
Stocks in the news: HUL, IDBI Bank, Oberoi Realty, Power Grid, Dilip Buildcon, DHFL
IDBI Bank | Oberoi Realty | Power Grid Corporation | Dilip Buildcon | DHFL | Nalco and Premier Explosives are stocks which are in the news today.
Moneycontrol
Like
Reply
N
Reputation: 13,930 • May 31, 2019 11:18 AM
Like
Reply

*BIG BUY BAL PHARMA*

*CMP 72.50*

*TG 78/80/82*

*SL 67*
2
Reply (11)
See all replies
RJ ROCKET TRADES @RISHABHTYAGI
Apr 26, 2019 4:20 AM

**BALPHARMA GUYS 78.30 FROM 72.50
T1 HIT IN 15 MINS

BIG BREAKOUT IN THE SCRIP

UP BY 11.50%**
RJ ROCKET TRADES @RISHABHTYAGI
Apr 26, 2019 4:24 AM

**NEXT BREAKOUT LEVEL OF BALPHARMA ABOVE 78 GATES OPEN UPTO 80-85**
RJ ROCKET TRADES @RISHABHTYAGI
Apr 26, 2019 4:34 AM

**8.5 % RETURN IN BALPHARMA IN INTRADAY😍😍**
S
Reputation: 3,115 • Mar 5, 2019 3:46 AM

One of midcap pharma favorite counter. Making base @65-70 zones add till 67-69 in dips for targets 89-98-120. In 2 months approx. Positive till hold 60 closing basis.

Disclaimer-educational purpose only.
BALPHARMA - 100453
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • BALPHARMA - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization99.9
    Enterprise Value192.63
    Price to Earnings18.42
    Price to Book Value1.3
    Return on Capital Employed0.11
    Return on Equity0.08
    Face Value10
    Dividend Yield0.01
  • BALPHARMA Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 2993.1596.4593.1594.8
    Jul 2898.598.592.5594.45
    Jul 2797.0598.99696.8
    Jul 2697.598.196.596.9
    Jul 23100.25100.2596.597.5
  • BALPHARMA Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹101.23
    30 Day Moving Average₹87.46
    50 Day Moving Average₹74.68
    100 Day Moving Average₹63.63
    200 Day Moving Average₹52.46
  • BALPHARMA - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue207.66225.96-0.08
    Operating Profit22.7819.590.16
    Profit Before Tax8.458.070.05
    Net Income5.944.970.2
  • BALPHARMA - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds76.8672.230.06
    Total Liabilities180.29171.50.05
    Total Assets257.15243.730.06
  • BALPHARMA - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity5.945.460.09
    Cash from Investing Activity-10.06-7.590.33
    Cash from Financing Activity3.532.280.55
    Net Cash Flow-0.590.15-4.93
  • BALPHARMA - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.020.02
    Return on Equity0.080.07
    Return on Capital Employed0.110.12
  • BALPHARMA - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.11
    3 Year CAGR Growth in Operating Profit0.3
    3 Year CAGR Growth in EBIDTA0.3
    3 Year CAGR Growth in Net Income0.48
    3 Yr CAGR Growth - Diluted EPS0.34
  • BALPHARMA - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.4
    5 Year CAGR Growth in Operating Profit0.32
    5 Year CAGR Growth in EBIDTA0.37
    5 Year CAGR Growth in Net Income0.39
    3 Yr CAGR Growth - Diluted EPS0.03
  • BALPHARMA - Recent News

    keyboard_arrow_down
    NewsBot
    May 25 4:06 AM
    Bal Pharma stock hits upper circuit on affordable Favipiravir launch
    The Economic Times
    NewsBot
    May 24 12:41 PM
    Bal Pharma launches antiviral drug Favipiravir at Rs 85/tablet
    The Economic Times
    NewsBot
    Feb 18 4:23 AM
    NewsBot
    Feb 14 5:38 AM
    NewsBot
    Aug 28, 2019 1:38 AM
    Stocks in the news: HUL, IDBI Bank, Oberoi Realty, Power Grid, Dilip Buildcon, DHFL
    Moneycontrol
    NewsBot
    May 31, 2019 11:18 AM
    NewsBot
    Apr 5, 2019 3:48 AM
    NewsBot
    Feb 13, 2019 11:42 AM
    NewsBot
    Dec 3, 2018 5:32 AM
  • BALPHARMA - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020